SCA
LPCN icon

Snowden Capital Advisors’s Lipocine LPCN Stock Holding History

Snowden Capital Advisors’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-740
Closed -$4K – 1199
2023
Q1 		$4K Hold
740
– – ﹤0.01% 1146
2022
Q4 		$5K Hold
740
– – ﹤0.01% 1128
2022
Q3 		$5K Hold
740
– – ﹤0.01% 1108
2022
Q2 		$10K Buy
+740
New +$11.5K ﹤0.01% 1115

Other funds holding LPCN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Snowden Capital Advisors's LPCN Position: Q2 2023 in Review

Snowden Capital Advisors sold out of Lipocine (LPCN) in Q2 2023, closing a stake of 740 shares — an estimated $4K sold.

Snowden Capital Advisors first reported a position in LPCN in Q2 2022 and held it in 4 quarters. The position peaked at $10K in Q2 2022. 24 funds tracked by Wall St. Rank hold LPCN as of Q2 2023.

  • Snowden Capital Advisors reported no remaining Lipocine position as of Q2 2023 after selling out during the quarter.
  • Snowden Capital Advisors sold 740 Lipocine shares in Q2 2023, an estimated $4K.
  • Snowden Capital Advisors first reported a position in Lipocine in Q2 2022 and held it in 4 quarters.
  • Snowden Capital Advisors's Lipocine position peaked at $10K in Q2 2022.
  • 24 funds tracked by Wall St. Rank held Lipocine as of Q2 2023.

Based on Snowden Capital Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.